After a long Michigan winter, many of us are in need of some extra vitamin D. If you are a patient with either Crohn’s or Ulcerative Colitis, you may be even more depleted than others.

Now is a good time to have your levels tested and see if you could benefit from a temporary increase in your supplements.

Since supplement doses vary, always make sure you talk to your doctor about the right dose for you. Foods like oily fish, mushrooms and egg yolks are also a good way of getting Vitamin D into your diet.

We would like to welcome Carolyn Graham as the newest member to our IBD research family. She will be working on the TWINE study as our care coordinator. Her role is to facilitate the more nuanced care for our higher risk IBD patients. We are happy to have her, and look forward to the beneficial change she will make in our patient’s lives!

The 4th Annual Patient-2-Patient Education Project

**What:** Together the Michigan Crohn’s and Colitis Student Initiative & Michigan IBD Program invite you to a FREE informational event for IBD patients and their friends/families

**When:** Saturday, April 13th from 10am-3pm

**Where:** Palmer Commons, 100 Washtenaw Ave
Ann Arbor, MI 48109

Refreshments & Lunch will be provided!
Limited seats available.

**RSVP at**
https://p2pemp19.eventbrite.com
Contact Kaicy Dettmann with any questions! (734) 936-4233
kaicdett@med.umich.edu
Currently Enrolling Clinical Trials

**Ulcerative Colitis**

**ABT494—Upadacitinib**
*Oral tablet (Recruitment on hold until Aug. 2018)*
This is a phase 2b/3 study for patients with moderate to severe Ulcerative Colitis to evaluate the safety and effectiveness of a new medication targeting JAK1.

**Figaro—SHP647**
*Subcutaneous injection*
This is a phase 3 study to evaluate the safety and efficacy of SHP647 in patients with moderate to severe Ulcerative Colitis. If eligible you will go through a 12 week induction, 52 week maintenance and a long term open label until the drug is approved by the FDA.

**Carmen—SHP647**
*Subcutaneous Injection*
This is a phase 3 study to evaluate the safety and efficacy of SHP647 in patients with moderate to severe Crohn’s Disease. If eligible you will go through a 12 week induction, 52 week maintenance and a long term open label until the drug is approved by the FDA.

**M16-006—Risakinumab**
*IV Induction / Subcutaneous injections for maintenance*
This is a phase 3 study to evaluate the safety and efficacy of Risakinumab in subjects with moderate to severe Crohn’s Disease.

**ABT494—Upadacitinib**
*Oral tablet*
This is a phase 3 study to evaluate the safety and efficacy of Upadacitinib in subjects with moderate to severe Crohn’s Disease. If eligible, subjects could be in the study for up to 244 weeks.

**Observational**

**Biofire:** To determine if intestinal infections are associated with flares of irritable bowel syndrome with diarrhea

**Databank:** Collect various samples from healthy volunteers and those with IBD

**FitBit Steroid Taper:** Track the outcomes of steroid tapers with the use of a FitBit wristband. The FitBit will monitor activity levels, sleep and heart rate in order to predict the outcomes of steroid tapers and predict future flares. Patients who are tapering off of prednisone and have Ulcerative Colitis or Crohn’s Disease are eligible to participate.

**PASS:** To learn more about long-term use and safety of Vedolizumab used in IBD treatment

**Sparc:** Identify new tests to predict who will respond to what treatment

**Target:** 5 year study for adults and pediatrics to specifically address clinical questions that remain unanswered from registration trials

**3D Printed Custom Ostomy Wafer:** To improve the quality and design of traditional ostomy wafers by 3D printing customized silicone wafers for patients. Patients with ostomies are eligible to participate.